BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Fluoptics Develops its Activities in North America


4/26/2012 8:53:56 AM

GRENOBLE, France and CAMBRIDGE, Massachusetts, April 25, 2012 /PRNewswire/ --

Fluoptics, a French company specialized in fluorescence image-guided surgery, announced today that it has opened an office in Cambridge (Massachusetts, USA) for the sales and marketing of its innovative solutions for preclinical in vivo fluorescence imaging.

Fluoptics develops integrated solutions combining a non-radioactive fluorescent tracer targeting cancer cells and a real-time optical imaging system called FluobeamTM. This proprietary device, which is due to enter clinical trials this year in Europe, is already available to the preclinical research market, where more than 15 units have been sold worldwide.

"The development of our activities in North America is a strategic decision following increased interest from US labs in our innovative solutions, after the first sale of FluobeamTM to a reference laboratory in Wisconsin," says Odile Allard, CEO of Fluoptics. "We will now work on accelerating the distribution of our preclinical instruments in the US and Canada directly or through key partnerships."

For preclinical research, the in vivo fluorescence imaging systems Fluobeam are already used with small and large animals, in fields such as cancer, drug development, cardiovascular, inflammation and infectious diseases. The FluobeamTM design is unique with its hand-held optical head and its live acquisition of the fluorescent signal.

Once approved for the clinical market, Fluoptics' technology will assist surgeons in the operating room in seeing what the naked eye cannot see. For example, in cancer surgery, it will allow "illuminating" cancer cells that will become visible in real time to the surgeon performing the resection of cancerous tumors, using natural light.

About Fluoptics

Founded in 2009, Fluoptics develops and markets innovative solutions in the fields of preclinical imaging and image-guided surgery. This technology has many applications, among others in oncology, for the detection and resection of tumours and metastasis, but also during surgery for lymph nodes detection, cardiovascular imaging, and liver research. The technology has been awarded many prizes and benefits from a portfolio of patents from Fluoptics' research partners. Based in Grenoble, Fluoptics has 11 employees for a turnover of 560 k in 2011. See also : http://www.fluoptics.com

SOURCE Fluoptics



Read at BioSpace.com

Fluoptics
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES